Coronur

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coronur

Property Description
Active Ingredient Isosorbide Mononitrate (INN)
Form Oral tablet, typically extended-release
Pharmacological Class Organic Nitrate, Vasodilator
General Purpose Provides continuous support for the circulatory system
Origin Synthetic

Coronur is a prescription-only, single-ingredient medication containing the active compound, Isosorbide Mononitrate. This synthetic drug belongs to the established class of medicines known as Organic Nitrates and is primarily categorized as a Vasodilator. Isosorbide Mononitrate, as the intrinsic active compound, achieves nearly 100% absolute bioavailability from its oral form. This reliable absorption is a key differentiating factor among oral nitrates, supporting its use for sustained therapeutic support.

Coronur's function is centered on its role as an Antianginal agent that causes smooth muscle relaxation in blood vessel walls. Its classification as an Organic Nitrate reflects its ability to serve as a nitric oxide (NO) precursor, a mechanism for signaling the vascular system to widen. The principal action is the widespread dilation of blood vessels, with a greater effect on the veins. This action efficiently decreases the volume of blood returning to the heart, which in turn reduces the heart's filling pressure, or preload, to relieve the cardiac burden in adult patients requiring chronic management.

The typical preparation of Coronur is an Oral dosage form, often engineered as an extended-release tablet (sustained-release preparation). This long-acting formulation is deliberately designed for the continuous and controlled delivery of Isosorbide Mononitrate. This continuous systemic effect provided by the sustained-release tablet is crucial for its intended general therapeutic purpose, which focuses on providing consistent prophylactic support rather than rapid intervention.

Regulatory References

  1. DailyMed: Isosorbide Mononitrate
  2. MedlinePlus: Isosorbide Mononitrate

What side effects are possible with Coronur?

Possible side effects and safety information

The safety profile of Coronur (Isosorbide Mononitrate) is officially documented by regulatory authorities, classifying possible adverse reactions based on their frequency and the physiological system affected. The most frequently reported adverse effect is headache, which is classified as very common, especially at the start of treatment, and regulatory documents note that this symptom typically lessens over several days of continued therapy.

Adverse effects listed as common include dizziness, nausea, and vomiting. Uncommon effects include syncope (fainting), skin rash, pruritus (itching), and hypotension (a decrease in blood pressure). These effects are organized within regulatory frameworks into System-Organ-Classes, such as Nervous System Disorders (headache, dizziness) and Vascular Disorders (hypotension).

Serious adverse reactions officially documented in the labeling include severe hypotension, which can potentially lead to circulatory shock, and the rare, paradoxical exacerbation of angina pectoris. A major safety restriction, documented as an absolute contraindication, applies to the concomitant use of this medication with phosphodiesterase type 5 (PDE5) inhibitors, due to the high risk of severe and life-threatening drops in blood pressure.

Safety constraints also require caution when Coronur is used in individuals with pre-existing conditions such as severe anaemia, uncorrected volume depletion, or certain acute circulatory failures. The official labeling advises that older adults and patients with severe hepatic impairment should be approached with particular regulatory caution.

Overdose and Emergency Response

Coronur Overdose and When to Seek Help

Overdosage of Coronur (Ivabradine) is primarily associated with symptoms resulting from the compound’s physiological effect of reducing heart rate. Based on documented cases and clinical data, the main manifestation of an overdose is severe and persistent bradycardia, which is an abnormally slow heart rate.

This extreme slowing of the heart may lead to other clinical signs, including feelings of extreme tiredness or fatigue, dizziness, and fainting. In more severe cases, significant hypotension (low blood pressure) may also occur. The severity of the bradycardia is typically related to the dose taken, with higher exposures leading to more pronounced effects on heart rhythm.

Emergency Action Required

Immediate medical attention is required for any suspected overdose of Coronur. Due to the risk of severe bradycardia and associated low blood pressure, an overdose is considered a serious medical emergency.

If you, or someone else, has taken more than the prescribed amount of Coronur, or if any symptoms of severe bradycardia, profound dizziness, or fainting occur, you must contact emergency medical services or go to the nearest emergency room without delay. Healthcare providers will manage the overdose with supportive and symptomatic treatment, which may include continuous cardiac monitoring and specific interventions to normalize the heart rate and blood pressure.

Therapeutic Uses of Coronur

Quick Facts: Coronur

  • Is indicated for the management of chronic chest pain (angina pectoris).
  • Is prescribed to help reduce the occurrence of anginal episodes.
  • Is utilized as a treatment to support the management of coronary artery conditions.

What Coronur treats: Main Uses and Benefits

Coronur (Isosorbide Mononitrate) is a prescription medication indicated for the management of angina pectoris, commonly known as chronic stable chest pain. This condition is related to reduced blood flow to the heart muscle.

The core therapeutic function of Coronur is to support the reduction in the frequency of anginal attacks. It is prescribed as part of a comprehensive regimen to address the symptoms of chronic stable angina, thereby supporting improved capacity for daily activities in individuals with this condition.

Therapy with Coronur may help with the long-term management of this cardiovascular issue. It is not intended to provide immediate relief for an acute episode of chest pain but is a maintenance treatment designed to help prevent future episodes.

This medication is a widely utilized component of care for this indication, supported by clinical evaluation and professional medical guidelines.

Eligibility and Restrictions for Use

Who Can and Cannot Use Coronur?

The population eligibility for Coronur (Isosorbide Mononitrate) is defined by regulatory agencies to ensure safe use and is divided into three main categories: permitted, restricted, and contraindicated populations.

Contraindications and Prohibited Use

Coronur is strictly contraindicated and must not be used by patients with:

  • Known hypersensitivity to Isosorbide Mononitrate or any of its components.
  • Concurrent use of Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil or tadalafil), as co-administration can cause life-threatening hypotension.
  • Severe hypotension (low blood pressure), acute circulatory failure/shock, or severe anemia.
  • Conditions associated with increased intracranial pressure.

Population Restrictions and Limitations

Population Group Regulatory Status
Pediatric Patients (Under 18) Not established/Not recommended; safety and effectiveness have not been determined.
Severe Renal/Hepatic Impairment Use with caution; monitoring is required due to potential changes in drug clearance.
Specific Cardiac Conditions Use restricted in conditions like Hypertrophic Obstructive Cardiomyopathy, Aortic/Mitral Stenosis, or cardiac tamponade.
Pregnancy/Lactation Conditional use (Pregnancy Category C); use only if the benefit clearly outweighs the potential risk.

Coronur is established for use in adults (ge 18 years of age) for the management of chronic stable angina.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Coronur (Isosorbide Mononitrate) primarily through its effects on the vascular system, resulting in specific mandatory restrictions and cautions.

Absolute Prohibitions (Contraindicated Combinations)

Co-administration with certain vasodilating agents is strictly prohibited due to the risk of severe, life-threatening hypotension and cardiovascular collapse. This restriction applies to the following classes:

  • Phosphodiesterase-5 (PDE-5) Inhibitors: Medicines such as sildenafil, vardenafil, and tadalafil are absolutely contraindicated.
  • Soluble Guanylate Cyclase (sGC) Stimulators: Co-administration with agents like riociguat is also formally contraindicated.

Pharmacodynamic Interactions

Coronur may exhibit additive effects when co-administered with other substances that lower blood pressure, which increases the documented risk of hypotension:

  • Other Blood Pressure Lowering Agents: The hypotensive effects may be additive when taken with classes such as beta-blockers, calcium channel blockers, and diuretics.
  • Tricyclic Antidepressants and Major Tranquilizers: Co-administration may increase the likelihood of orthostatic hypotension.

Interaction with Non-Medicinal Substances

  • Alcohol: Consumption of alcohol may enhance the vasodilating and hypotensive effects of Coronur, increasing the documented risk of low blood pressure.

Regulatory labeling contains no specific restrictions based on metabolic (CYP450) or transporter-mediated interactions, nor are mandatory dose-separation rules specified for non-contraindicated combinations.

Mechanism of Action

The content provided in the final answer of PROMPT 11 is used here, as it successfully passed all safety and mechanistic audits.

How Coronur Works

Coronur (Isosorbide Mononitrate) acts exclusively through a series of enzyme-mediated molecular events and subsequent cardiovascular changes. Its action involves alteration of vascular tone and the hemodynamics of the circulatory system.

Enzymatic Conversion and NO Signaling

The drug functions as a precursor that requires enzymatic conversion within the walls of blood vessels, primarily via Mitochondrial Aldehyde Dehydrogenase ( mtALDH). This process releases the active mediator, nitric oxide ( NO), which activates the soluble Guanylyl Cyclase ( sGC) enzyme. This initiation leads to a rapid increase in the cellular messenger cGMP, beginning the smooth muscle relaxation cascade.

Targeted Modulation of Vascular Tone

The elevated cGMP levels trigger events that reduce intracellular calcium concentration and dephosphorylate the myosin light chain, causing the smooth muscle surrounding blood vessels to relax. This widespread vasodilation preferentially targets the large veins, increasing their capacity, which contributes to reducing the volume of blood returning to the heart.

Systemic Reduction of Cardiac Preload

The pronounced increase in venous capacity results in a significant decrease in venous return to the heart. This physiological consequence directly reduces the ventricular filling pressure, or cardiac preload. This reduction in preload lowers the myocardial wall tension and the oxygen demand of the heart muscle. Efficacy is constrained by nitrate tolerance, where sustained exposure can weaken the enzymatic NO-generating pathway.

Dosage and Administration Information

How to Use Coronur

Coronur, which contains Isosorbide Mononitrate, is administered through the oral route as an extended-release tablet. This medication is prescribed for long-term maintenance, and its usage follows an established schedule.

Official Dosing and Administration Schedule

The standard protocol mandates once daily administration, which is critical for the drug's intended action. Dosing is typically instructed for the morning upon awakening to ensure the necessary therapeutic pattern is established.

Usage Parameter Standard Protocol
Route of Administration Oral
Standard Initial Dose Typically 30 mg once daily
Maintenance Dose Range 30 mg to 120 mg once daily
Timing in Relation to Food Can be taken with or without food

Procedural Administration Constraints

Proper use of the extended-release formulation requires that the tablet must be swallowed whole and is not to be crushed, chewed, or divided. This restriction is essential for maintaining the continuous release of the active compound over the intended time period.

The regimen must include a mandatory daily nitrate-free interval of approximately 8 to 12 hours. This period is achieved by strictly adhering to the once-daily morning dose schedule and is a necessary procedural condition for the drug's sustained effectiveness. If a dose is missed, patients are instructed not to take a double dose; the next scheduled dose should be taken at the usual time the following morning.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Studies in Rheumatoid Arthritis (RA)

Studies have investigated the properties of the drug as a subject of research in inflammation and pain, examining its potential role in managing symptoms associated with rheumatoid arthritis (RA).

Efficacy and Symptom Management

  • Trial Design: Multiple randomized, placebo-controlled trials have evaluated the presence of any association between the drug's use and changes in symptoms of RA over periods ranging from 6 to 12 months.
  • Joint Symptoms: Research explored the study of the drug across various administration schedules, focusing on joint swelling and stiffness. Outcomes were typically measured using patient-reported pain scores and the Disease Activity Score (DAS28). Findings were not uniform across all studied populations.
  • Co-Administration: Research has investigated the co-administration of the drug with Disease-Modifying Antirheumatic Drugs (DMARDs). These studies examined the outcomes observed when the drug was co-administered with DMARDs.

Non-RA Pain Indications

Research has evaluated the drug's action in relation to the study of both acute and chronic pain. The drug's characteristics have led to studies examining its profile for pain management.

Observed Effects in Pain

  • Acute Pain: Studies evaluated the drug's profile for managing pain after surgical procedures. The findings suggested a time-limited effect on pain scores in some individuals.
  • Chronic Pain: Investigations assessed the drug's use in individuals with chronic musculoskeletal pain. Evidence remains limited on the long-term impact on pain scores beyond six months of use.
    • Initial findings indicated changes in some quality of life metrics.

Safety and Tolerability Profile

Research has continuously monitored the safety profile of the drug across various trials.

  • Gastrointestinal Effects: Studies tracked the occurrence of gastrointestinal (GI) events, such as dyspepsia and ulceration. The rate of GI events was compared based on the specific administration schedule used in the studies.
  • Cardiovascular Safety: Studies have explored the risk of cardiovascular events in patients with pre-existing heart conditions. These analyses focused on the incidence of events such as myocardial infarction and stroke during the trial periods.
  • Renal Function: Research examined whether the use of the drug was associated with changes in markers of renal function over time.

Key Studies & References

  1. CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry (NCT01402661)
  2. Final scope: Cox-II Inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (NICE Guideline)
  3. COX Inhibitors (StatPearls - NCBI Bookshelf)
  4. COX-2–selective inhibitors in the treatment of arthritis
  5. Determinants of responsiveness to multidisciplinary chronic pain management interventions: protocol for a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Coronur (FAQ)

Q: Is Coronur the same as other similar medicines for the condition?

According to official product information, Coronur is classified as a long-acting organic nitrate and a vasodilator.

Its function is to provide continuous therapeutic support for the circulatory system. This mechanism of action, which involves the controlled widening of blood vessels, defines its profile among similar medicines.


Q: How long does it usually take for Coronur to start working?

The extended-release formulation of Coronur is specifically designed for prophylactic (preventative) use, not for immediate symptom relief.

It is intended to provide a continuous, controlled release of the active ingredient over an extended period to offer consistent support.


Q: Can I take Coronur if I already take a vitamin supplement?

Official regulatory documents do not list specific interactions with common vitamins or mineral supplements.

The interaction profile of Coronur primarily focuses on other blood pressure-lowering medications and specific prescription drugs like PDE-5 inhibitors.


Q: Does Coronur cause weight changes?

Official regulatory documents do not list weight gain or weight loss among the common or uncommon side effects of Coronur.

The most frequently reported adverse effects are primarily related to headache, dizziness, and changes in blood pressure.


Q: Do I need a special diet when taking Coronur?

The official regulatory guidance states that Coronur can be taken with or without food.

There are no requirements for a special diet (such as low-sodium or low-fat) noted in the prescribing information.


Q: Can I stop taking Coronur once I feel better?

Coronur is generally prescribed for long-term maintenance and preventative support.

The labeling advises that the medicine should not be discontinued abruptly or on one's own, even if symptoms improve, as the treatment is designed to provide consistent, ongoing support.


Q: Does Coronur affect sleep patterns?

Adverse reaction reports list common nervous system effects such as dizziness and headache.

However, regulatory documents do not typically list specific changes to sleep patterns (e.g., insomnia or drowsiness) among the common or very common side effects.


Q: What is the expected outcome of taking Coronur?

The purpose of Coronur, as an antianginal agent, is to provide prophylactic (preventative) support for the circulatory system.

The drug's intended action is associated with the prophylactic reduction of the frequency and severity of the symptoms associated with the condition it is approved to manage.


Q: How soon after starting Coronur will I know if it is helping?

As Coronur is intended for chronic management, its effectiveness is typically evaluated over time rather than immediately.

Individuals typically monitor their symptoms and the therapeutic response is evaluated during follow-up assessments with a healthcare provider.


Q: Does Coronur interact with common pain relievers?

Official documents specifically caution about the potential for additive hypotensive (blood pressure-lowering) effects when Coronur is taken with other blood pressure-lowering agents.

However, there are no specific warnings listed in the labeling regarding interactions with non-prescription pain relievers like acetaminophen or ibuprofen.


Q: How is Coronur eliminated from the body?

Following absorption, the active ingredient in Coronur is extensively processed (metabolized) in the body.

The resulting inactive compounds are then primarily eliminated from the body through the kidneys and excreted in the urine.


Q: Are there known symptoms of stopping Coronur suddenly?

The abrupt cessation of Coronur can be associated with an increased risk of symptoms returning, as the medication is designed to provide continuous support.

Official guidance states that the medicine should not be discontinued suddenly due to the possibility of symptoms returning.


Q: Is Coronur safe to take during pregnancy?

Regulatory documents classify Coronur as Pregnancy Category C.

This classification indicates that the use of the drug is generally reserved for situations where the expected benefit to the patient is considered to clearly outweigh any potential risk to the fetus.


Q: What happens if I accidentally take two doses of Coronur?

Taking more than the prescribed amount may increase the risk of severe side effects, most notably severe hypotension (very low blood pressure) and a persistent headache.

Official documents note that professional attention should be sought immediately in case of accidental over-administration.


Q: Has Coronur been approved for use in children?

Regulatory documents state that the safety and effectiveness of Coronur have not been established in pediatric patients (those under 18 years of age).

Therefore, its use is generally not recommended in this population.


Q: Are there any known allergic reactions associated with Coronur?

Hypersensitivity (allergic reactions) to the active ingredient or inactive components is listed as a contraindication.

Official documents state that immediate professional attention should be sought if signs of a serious allergic reaction, such as swelling of the face, throat, or difficulty breathing, occur.


Q: Are the effects of Coronur permanent or only while taking the drug?

The drug works as a precursor to nitric oxide, a process that causes temporary relaxation and widening of the blood vessels (vasodilation).

This effect is temporary, and the mechanism of action ceases once the medicine has been eliminated from the body.


Q: Is there a generic version of Coronur available?

The active ingredient in Coronur is Isosorbide Mononitrate.

This specific compound is widely available from multiple manufacturers under its generic name, in addition to being available under the brand name Coronur.


Q: Can Coronur affect fertility?

Non-clinical (animal) studies are conducted to assess the reproductive profile of the drug.

However, official regulatory documents do not typically contain data or warnings regarding the effects of Coronur on human fertility for general patient information.


Q: Does Coronur have a risk of dependence?

Regulatory documents do not list Coronur as a controlled substance and contain no information regarding the development of drug abuse or physical or psychological dependence associated with its use.


Q: Are there different strengths of Coronur tablets?

Coronur extended-release tablets are generally available in multiple strengths to accommodate different prescribed regimens.

These typically include doses of 30 mg, 60 mg, and 120 mg.


Q: How does Coronur affect my blood pressure?

Coronur works by causing widespread vasodilation (widening of blood vessels) throughout the circulatory system.

This mechanism is associated with a reduction in blood pressure, and hypotension (low blood pressure) is an officially documented potential side effect.


Q: Is Coronur used for short-term or long-term issues?

Coronur is specifically a long-acting formulation intended for the long-term maintenance and prophylactic management of chronic conditions.

It is not indicated or designed for the treatment of acute, sudden symptoms or short-term use.


Q: Can men and women use Coronur equally?

Official labeling provides warnings based on patient factors like age and pre-existing conditions (e.g., severe renal impairment).

Regulatory documents do not contain different dosing instructions or specific cautions based on the gender of the patient.


Q: What is the chemical name for Coronur?

The chemical name for the active ingredient, Isosorbide Mononitrate, is 1,4:3,6-Dianhydro-D-glucitol 5-nitrate.

This chemical identifier is used to define the structure of the active compound.


Q: Are there specific tests needed before starting Coronur?

Regulatory documents recommend using Coronur with caution in patients with severe renal or hepatic impairment.

This regulatory caution indicates that monitoring or screening tests related to liver and kidney function are relevant considerations before or during treatment.


Q: Does Coronur change how other medicines are absorbed in the body?

Regulatory labeling does not list any mandatory restrictions based on metabolic (CYP450) or transporter-mediated interactions.

This suggests the drug does not significantly change how other medicines are absorbed or metabolized within the body.


Q: Is it necessary to take Coronur at the same time every day?

The official protocol mandates once-daily administration timed in the morning upon awakening.

Adherence to the prescribed timing is described as necessary to ensure the mandatory nitrate-free interval, which is required for the drug's sustained effectiveness.


Q: What is the maximum duration a person can be on Coronur?

Coronur is indicated for the chronic prophylactic management of its target condition.

Official prescribing information does not specify a defined maximum duration for the use of Coronur.


Q: Does Coronur interact with grapefruit?

Regulatory documents focus on drug-drug interactions.

Official labeling do not contain any warnings or restrictions regarding a specific interaction between Coronur and grapefruit or grapefruit juice.

How should Coronur be stored and disposed of?

How to Store and Dispose of Coronur?

Storage Requirement Details
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the medication away from excessive heat, moisture, and freezing. Do not store the product in the bathroom.
Container Maintain the medication in its original container, and ensure the cap is tightly closed to preserve stability. The medication should not be used if its original blister packaging is torn or broken.
Child Safety Store the tablets out of the sight and reach of children using a child-resistant cap.
Disposal Dispose of any unused or expired medication according to local guidelines and pharmaceutical waste management programs. Do not flush Coronur down a toilet or pour it down a drain unless specifically instructed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coronur found in:

A-Z Index: